Shares of Abbott India Ltd are trading flat after touching a day’s high of Rs 32,085 on 19th June. This announcement follows the company’s strategic distribution agreement with MSD Pharmaceuticals, which aims to expand access to MSD’s oral anti-diabetes drugs in India, including sitagliptin and its combination therapies.

Abbott has partnered with MSD Pharmaceuticals to distribute MSD’s sitagliptin-based diabetes medicines in India, including Januvia, Janumet, and Janumet XR. These brands remain leaders in the DPP-4 inhibitor segment, even after the sitagliptin patent expired in July 2022, allowing the market to be opened to lower-cost generics.

Sitagliptin, launched in India in 2008, helps manage type 2 diabetes by lowering HbA1c levels and improving blood sugar control. Despite generic competition, MSD maintains a strong position in this market.

India’s oral anti-diabetes market is valued at approximately Rs 12,500 crore, with DPP-4 inhibitors accounting for around Rs 4,000 crore. Globally, sitagliptin holds a share of over 60% in the DPP-4 market, making it a key treatment option.

With over 101 million Indians living with diabetes and another 136 million at risk, improving access to such treatments is an urgent public health need.

At 12:37 PM, the shares of Abbott India were trading 0.29% higher at Rs 31,655 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!